Literature DB >> 18007664

RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR.

D B Ramnarain1, R Paulmurugan, S Park, B E Mickey, A Asaithamby, D Saha, M A Kelliher, P Mukhopadhyay, F Banani, C J Madden, P S Wright, S Chakravarty, A A Habib.   

Abstract

There is considerable interest in understanding how inflammatory responses influence cell proliferation and cancer. In this study, we show that the receptor-interacting protein (RIP1), a critical mediator of inflammation and stress-induced NF-kappaB activation, regulates the expression of the epidermal growth factor receptor (EGFR). Mouse embryo fibroblasts (MEFs) derived from RIP1 knockout mice express very high levels of the EGFR. Reconstitution of RIP1(-/-) MEFs with RIP1 results in a lowering of EGFR levels. RIP1 influences EGFR at the mRNA level by regulating the EGFR promoter. Expression of RIP1 inhibits the EGFR promoter. RIP1 downregulates EGFR expression by interfering with the function of Sp1, which is a key activator of EGFR transcription. RIP1 suppresses Sp1 activity and overexpression of Sp1 reverses RIP1-mediated repression of the EGFR promoter. RIP1 is present both in the cytoplasm and in the nucleus. RIP1 coimmunoprecipitates with Sp1 in vivo and binds directly to Sp1 in vitro. A RIP1 mutant lacking the death domain fails to suppress Sp1 activity and the EGFR promoter, suggesting a critical role for the RIP1 death domain in EGFR regulation. Thus, our study identifies a new link between inflammatory and growth factor signaling pathways mediated by RIP1 and provides insight into the mechanism used by RIP1 to regulate EGFR levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007664     DOI: 10.1038/sj.cdd.4402268

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  14 in total

1.  RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection.

Authors:  Yee Soo Chae; Jong Gwang Kim; Sang Kyun Sohn; Su Jeong Lee; Byung Woog Kang; Joon Ho Moon; Jae Yong Park; Seong Woo Jeon; Han-Ik Bae; Gyu Seog Choi; Soo-Han Jun
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-22       Impact factor: 4.553

2.  RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression.

Authors:  Waise Quarni; Panida Lungchukiet; Anfernee Tse; Pei Wang; Yuefeng Sun; Ravi Kasiappan; Jheng-Yu Wu; Xiaohong Zhang; Wenlong Bai
Journal:  J Steroid Biochem Mol Biol       Date:  2017-02-01       Impact factor: 4.292

Review 3.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

4.  An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.

Authors:  L Li; S Chakraborty; C-R Yang; K J Hatanpaa; D J Cipher; V T Puliyappadamba; A Rehman; A J Jiwani; B Mickey; C Madden; J Raisanen; S Burma; D Saha; Z Wang; S C Pingle; S Kesari; D A Boothman; A A Habib
Journal:  Oncogene       Date:  2013-09-30       Impact factor: 9.867

5.  The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine.

Authors:  E Garrido; T Palomo; G Ponce; I García-Consuegra; M A Jiménez-Arriero; J Hoenicka
Journal:  Neurotox Res       Date:  2010-09-16       Impact factor: 3.911

6.  The death domain-containing kinase RIP1 regulates p27(Kip1) levels through the PI3K-Akt-forkhead pathway.

Authors:  Seongmi Park; Deepti B Ramnarain; Kimmo J Hatanpaa; Bruce E Mickey; Debabrata Saha; Ramasamy Paulmurugan; Christopher J Madden; Paul S Wright; Salman Bhai; M Aktar Ali; Krishna Puttaparthi; Wei Hu; Jeffrey L Elliott; Olaf Stuve; Amyn A Habib
Journal:  EMBO Rep       Date:  2008-06-20       Impact factor: 8.807

7.  Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors.

Authors:  Fatemeh Karami-Tehrani; Amin Rahimi Malek; Zahra Shahsavari; Morteza Atri
Journal:  Tumour Biol       Date:  2016-01-09

8.  Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.

Authors:  Kevin D McCormick; Arundhati Ghosh; Sumita Trivedi; Lin Wang; Carolyn B Coyne; Robert L Ferris; Saumendra N Sarkar
Journal:  Carcinogenesis       Date:  2016-03-18       Impact factor: 4.944

9.  The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma.

Authors:  Seongmi Park; Kimmo J Hatanpaa; Yang Xie; Bruce E Mickey; Christopher J Madden; Jack M Raisanen; Deepti B Ramnarain; Guanghua Xiao; Debabrata Saha; David A Boothman; Dawen Zhao; Robert M Bachoo; Russell O Pieper; Amyn A Habib
Journal:  Cancer Res       Date:  2009-04-01       Impact factor: 12.701

10.  Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.

Authors:  Sahar A Saddoughi; Salih Gencer; Yuri K Peterson; Katherine E Ward; Archana Mukhopadhyay; Joshua Oaks; Jacek Bielawski; Zdzislaw M Szulc; Raquela J Thomas; Shanmugam P Selvam; Can E Senkal; Elizabeth Garrett-Mayer; Ryan M De Palma; Dzmitry Fedarovich; Angen Liu; Amyn A Habib; Robert V Stahelin; Danilo Perrotti; Besim Ogretmen
Journal:  EMBO Mol Med       Date:  2012-11-25       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.